Aggressive’ Bearish Options Activity Seen in AstraZeneca plc (ADR)

 Aggressive' Bearish Options Activity Seen in AstraZeneca plc (ADR)

In today’s session AstraZeneca plc (ADR) (AZN) recorded an unusually high (1,894) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious AZN decrease. With 1,894 contracts traded and 76534 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: AZN161118P00027500 closed last at: $0.75 or 150% up. About 1.16 million shares traded hands. AstraZeneca plc (ADR) (NYSE:AZN) has risen 0.25% since March 29, 2016 and is uptrending. It has underperformed by 3.23% the S&P500.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on November, 3. They expect $0.58 EPS, down 43.69% or $0.45 from last year’s $1.03 per share. AZN’s profit will be $1.44B for 12.27 P/E if the $0.58 EPS becomes a reality. After $0.83 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -30.12% negative EPS growth.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. $50 is the highest target while $32 is the lowest. The $38.40 average target is 34.88% above today’s ($28.47) stock price. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Oddo & Cie upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Tuesday, January 26 to “Top Pick” rating. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Overweight” rating given on Friday, September 23 by Piperjaffray. The firm earned “Neutral” rating on Wednesday, September 14 by BNP Paribas. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Buy” rating by S&P Research on Friday, July 31. As per Friday, September 18, the company rating was upgraded by Bryan Garnier & Cie. The firm has “Buy” rating by Jefferies given on Monday, September 12. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, December 1. The rating was maintained by Leerink Swann on Monday, May 2 with “Market Perform”. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Hold” rating by HBSC on Monday, February 8. On Tuesday, March 15 the stock rating was downgraded by Jefferies to “Hold”.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $70.85 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 32.43 P/E ratio. The Firm has its activities in over 100 countries.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Businessfinancenews.com which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment